$MOH
MOLINA HEALTHCARE, INC. Stock $moh

$moh Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000117992922000025 Filed on February 14, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$7.409B	$27.77B	$5.235B
YoY Change	41.53%	42.98%	22.48%
Cost Of Revenue	$6.362B	$23.70B	$4.408B
YoY Change	44.33%	49.84%	24.34%
Gross Profit	$1.047B	$4.067B	$827.0M
YoY Change	26.6%	64.06%	43.08%
Gross Profit Margin	14.13%	14.64%	15.8%
Selling, General & Admin	$790.0M	$2.821B	$690.0M
YoY Change	14.49%	18.03%	48.39%
% of Gross Profit	75.45%	69.36%	83.43%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$35.00M	$131.0M	$24.00M
YoY Change	45.83%	48.86%	14.29%
% of Gross Profit	3.34%	3.22%	2.9%
Operating Expenses	$825.0M	$2.952B	$714.0M
YoY Change	15.55%	19.13%	46.91%
Operating Profit	$222.0M	$1.020B	$113.0M
YoY Change	96.46%	-5.38%	22.83%
Interest Expense	-$30.00M	$120.0M	-$30.00M
YoY Change	0.0%	17.65%	50.0%
% of Operating Profit	-13.51%	11.76%	-26.55%
Other Income/Expense, Net	-$25.00M	-$145.0M
YoY Change		23.93%
Pretax Income	$136.0M	$875.0M	$51.00M
YoY Change	166.67%	-8.95%	-77.03%
Income Tax	$33.00M	$216.0M	$17.00M
% Of Pretax Income	24.26%	24.69%	33.33%
Net Earnings	$103.0M	$659.0M	$34.00M
YoY Change	202.94%	-2.08%	-79.76%
Net Earnings / Revenue	1.39%	2.37%	0.65%
Basic Earnings Per Share		$11.40
Diluted Earnings Per Share	$1.749M	$11.25	$566.7K
COMMON SHARES
Basic Shares Outstanding	58.40M shares	57.80M shares	59.30M shares
Diluted Shares Outstanding		58.60M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.640B	$7.640B	$6.029B
YoY Change	26.72%	26.72%	37.09%
Cash & Equivalents	$4.438B	$4.438B	$4.154B
Short-Term Investments	$3.202B	$3.202B	$1.875B
Other Short-Term Assets	$247.0M	$247.0M	$175.0M
YoY Change	41.14%	41.14%	7.36%
Inventory
Prepaid Expenses
Receivables	$2.177B	$2.177B	$1.672B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.06B	$10.06B	$7.876B
YoY Change	27.78%	27.78%	31.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$396.0M	$524.0M	$462.0M
YoY Change	-14.29%	13.42%	2.67%
Goodwill	$982.0M		$692.0M
YoY Change	41.91%		383.92%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$179.0M	$369.0M	$119.0M
YoY Change	50.42%	45.85%	13.33%
Total Long-Term Assets	$2.145B	$2.145B	$1.656B
YoY Change	29.53%	29.53%	101.95%
TOTAL ASSETS
Total Short-Term Assets	$10.06B	$10.06B	$7.876B
Total Long-Term Assets	$2.145B	$2.145B	$1.656B
Total Assets	$12.21B	$12.21B	$9.532B
YoY Change	28.08%	28.08%	40.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$842.0M	$792.0M	$608.0M
YoY Change	38.49%	30.26%	44.08%
Accrued Expenses		$35.00M	$21.00M
YoY Change		66.67%	-16.0%
Deferred Revenue	$370.0M		$375.0M
YoY Change	-1.33%		50.6%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$15.00M	$0.00
YoY Change		25.0%	-100.0%
Total Short-Term Liabilities	$7.047B	$7.047B	$4.965B
YoY Change	41.93%	41.93%	51.88%
LONG-TERM LIABILITIES
Long-Term Debt	$2.173B	$2.392B	$2.127B
YoY Change	2.16%	1.7%	71.95%
Other Long-Term Liabilities	$140.0M	$140.0M	$119.0M
YoY Change	17.65%	17.65%	32.22%
Total Long-Term Liabilities	$2.313B	$2.532B	$2.246B
YoY Change	2.98%	2.47%	69.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.047B	$7.047B	$4.965B
Total Long-Term Liabilities	$2.313B	$2.532B	$2.246B
Total Liabilities	$9.579B	$9.579B	$7.436B
YoY Change	28.82%	28.82%	54.05%
SHAREHOLDERS EQUITY
Retained Earnings	$2.399B		$1.860B
YoY Change	28.98%		4.44%
Common Stock	$236.0M		$199.0M
YoY Change	18.59%		13.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.630B	$2.630B	$2.096B
YoY Change
Total Liabilities & Shareholders Equity	$12.21B	$12.21B	$9.532B
YoY Change	28.08%	28.08%	40.44%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$103.0M	$659.0M	$34.00M
YoY Change	202.94%	-2.08%	-79.76%
Depreciation, Depletion And Amortization	$35.00M	$131.0M	$24.00M
YoY Change	45.83%	48.86%	14.29%
Cash From Operating Activities	$597.0M	$2.119B	$1.299B
YoY Change	-54.04%	11.64%	4379.31%
INVESTING ACTIVITIES
Capital Expenditures	-$21.00M	$77.00M	-$10.00M
YoY Change	110.0%	4.05%	-62.96%
Acquisitions		$129.0M
YoY Change		-82.91%
Other Investing Activities	-$526.0M	$63.00M	-$488.0M
YoY Change	7.79%	-3250.0%	162.37%
Cash From Investing Activities	-$547.0M	-$1.653B	-$498.0M
YoY Change	9.84%	313.25%	133.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$128.0M
YoY Change		-78.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.00M	-$183.0M	156.0M
YoY Change	-86.54%	-184.33%	-471.43%
NET CHANGE
Cash From Operating Activities	597.0M	$2.119B	1.299B
Cash From Investing Activities	-547.0M	-$1.653B	-498.0M
Cash From Financing Activities	21.00M	-$183.0M	156.0M
Net Change In Cash	71.00M	$283.0M	957.0M
YoY Change	-92.58%	-83.5%	-523.45%
FREE CASH FLOW
Cash From Operating Activities	$597.0M	$2.119B	$1.299B
Capital Expenditures	-$21.00M	$77.00M	-$10.00M
Free Cash Flow	$618.0M	$2.042B	$1.309B
YoY Change	-52.79%	11.95%	2237.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001179929
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	1-31719
CY2021	dei	Entity Registrant Name EntityRegistrantName	MOLINA HEALTHCARE, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-4204626
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Oceangate
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Long Beach
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90802
CY2021	dei	City Area Code CityAreaCode	562
CY2021	dei	Local Phone Number LocalPhoneNumber	435-3666
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	MOH
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	14700000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58400000	shares
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	26855000000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	18299000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	16208000000	USD
CY2021	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	787000000	USD
CY2020	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	649000000	USD
CY2019	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	489000000	USD
CY2021	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	0	USD
CY2020	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	271000000	USD
CY2019	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	0	USD
CY2021	moh	Health Care Organization Marketplace Risk Corridor Judgment Revenue HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue	0	USD
CY2020	moh	Health Care Organization Marketplace Risk Corridor Judgment Revenue HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue	128000000	USD
CY2019	moh	Health Care Organization Marketplace Risk Corridor Judgment Revenue HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue	0	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	52000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	59000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	115000000	USD
CY2021	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	77000000	USD
CY2020	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	17000000	USD
CY2019	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	17000000	USD
CY2021	us-gaap	Revenues Revenues	27771000000	USD
CY2020	us-gaap	Revenues Revenues	19423000000	USD
CY2019	us-gaap	Revenues Revenues	16829000000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23704000000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15820000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13905000000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2068000000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1480000000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1296000000	USD
CY2021	moh	Premium Tax Expenses PremiumTaxExpenses	787000000	USD
CY2020	moh	Premium Tax Expenses PremiumTaxExpenses	649000000	USD
CY2019	moh	Premium Tax Expenses PremiumTaxExpenses	489000000	USD
CY2021	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	0	USD
CY2020	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	277000000	USD
CY2019	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	0	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	131000000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	88000000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	89000000	USD
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	61000000	USD
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	31000000	USD
CY2019	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	6000000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	26751000000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	18345000000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	15785000000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1020000000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	1078000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	1044000000	USD
CY2021	us-gaap	Interest Expense InterestExpense	120000000	USD
CY2020	us-gaap	Interest Expense InterestExpense	102000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	87000000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-145000000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117000000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-72000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	875000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	961000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	972000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	216000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	235000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	659000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	673000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	737000000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.40
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.40
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.25
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.23
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.47
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57800000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59000000.0	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62200000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58600000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59900000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64200000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	659000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	673000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	737000000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-55000000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	44000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	16000000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-13000000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	11000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	4000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-42000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	33000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	617000000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	706000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	749000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4438000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4154000000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3202000000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1875000000	USD
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	2177000000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1672000000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	247000000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	175000000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10064000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	7876000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	396000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	391000000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1252000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	941000000	USD
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	212000000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	136000000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	106000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	69000000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	179000000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	119000000	USD
CY2021Q4	us-gaap	Assets Assets	12209000000	USD
CY2020Q4	us-gaap	Assets Assets	9532000000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3363000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2696000000	USD
CY2021Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	2472000000	USD
CY2020Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	1253000000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	842000000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	641000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	370000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	375000000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7047000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4965000000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2173000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2127000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	219000000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	225000000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	140000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	119000000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	9579000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	7436000000	USD
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	236000000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	199000000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	37000000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2399000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1860000000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2630000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2096000000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12209000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9532000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1647000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	737000000	USD
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	54000000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-514000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	47000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1960000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	673000000	USD
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	605000000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-30000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	33000000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	65000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2096000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	659000000	USD
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	122000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-42000000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	39000000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2630000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	659000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	673000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	737000000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	88000000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89000000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	24000000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	19000000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-10000000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	72000000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	57000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	39000000	USD
CY2021	moh	Gain Loss On Debt Repayment GainLossOnDebtRepayment	-25000000	USD
CY2020	moh	Gain Loss On Debt Repayment GainLossOnDebtRepayment	-15000000	USD
CY2019	moh	Gain Loss On Debt Repayment GainLossOnDebtRepayment	15000000	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	33000000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	12000000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	415000000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	100000000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	76000000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19000000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16000000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28000000	USD
CY2021	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	471000000	USD
CY2020	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	544000000	USD
CY2019	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	-107000000	USD
CY2021	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	1046000000	USD
CY2020	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	446000000	USD
CY2019	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	-303000000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	138000000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	86000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9000000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5000000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	126000000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	38000000	USD
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	7000000	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-14000000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-15000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2119000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1898000000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	755000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	434000000	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2713000000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	670000000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2536000000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1329000000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1097000000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2302000000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	129000000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000000	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	63000000	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1653000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-400000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-293000000	USD
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	740000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1429000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	723000000	USD
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	338000000	USD
CY2019	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	128000000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	606000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	47000000	USD
CY2021	moh	Common Stock Withheld To Settle Employee Tax Obligations CommonStockWithheldToSettleEmployeeTaxObligations	53000000	USD
CY2020	moh	Common Stock Withheld To Settle Employee Tax Obligations CommonStockWithheldToSettleEmployeeTaxObligations	8000000	USD
CY2019	moh	Common Stock Withheld To Settle Employee Tax Obligations CommonStockWithheldToSettleEmployeeTaxObligations	7000000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	20000000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	600000000	USD
CY2019	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	380000000	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	220000000	USD
CY2021	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2020	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	30000000	USD
CY2019	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	514000000	USD
CY2021	moh	Cash Paid For Settlement Of Conversion Option CashPaidForSettlementOfConversionOption	0	USD
CY2020	moh	Cash Paid For Settlement Of Conversion Option CashPaidForSettlementOfConversionOption	27000000	USD
CY2019	moh	Cash Paid For Settlement Of Conversion Option CashPaidForSettlementOfConversionOption	578000000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	27000000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	578000000	USD
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12000000	USD
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	240000000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1000000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	29000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-183000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	217000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-559000000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	283000000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1715000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-418000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4223000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2508000000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2926000000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4506000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4223000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2508000000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	235000000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	321000000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	239000000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	127000000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	112000000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	78000000	USD
CY2021Q3	moh	Health Plan Contract Term HealthPlanContractTerm	P4Y
CY2021Q3	moh	Health Plan Extension Option Period HealthPlanExtensionOptionPeriod	P2Y
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4438000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4154000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2452000000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	68000000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	69000000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	56000000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4506000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4223000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2508000000	USD
CY2021	moh	Investments Maturity Period InvestmentsMaturityPeriod	P10Y
CY2021	moh	Investments Average Maturity Period InvestmentsAverageMaturityPeriod	P10Y
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	11000000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	10000000	USD
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	2177000000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1672000000	USD
CY2021Q4	moh	Amounts Dueto Government Agencies Other AmountsDuetoGovernmentAgenciesOther	48000000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	moh	Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold	18000000	USD
CY2020Q4	moh	Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold	37000000	USD
CY2021Q4	moh	Medical Premiums Liability Medical Care Costs Threshold MedicalPremiumsLiabilityMedicalCareCostsThreshold	1016000000	USD
CY2020Q4	moh	Medical Premiums Liability Medical Care Costs Threshold MedicalPremiumsLiabilityMedicalCareCostsThreshold	513000000	USD
CY2021Q4	moh	Amounts Due To Government Agencies Medicaid Other AmountsDueToGovernmentAgenciesMedicaidOther	263000000	USD
CY2020Q4	moh	Amounts Due To Government Agencies Medicaid Other AmountsDueToGovernmentAgenciesMedicaidOther	76000000	USD
CY2021Q4	moh	Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing	89000000	USD
CY2020Q4	moh	Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing	45000000	USD
CY2021Q4	moh	Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	101000000	USD
CY2020Q4	moh	Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	62000000	USD
CY2021Q4	moh	Other Medicare Program OtherMedicareProgram	35000000	USD
CY2020Q4	moh	Other Medicare Program OtherMedicareProgram	30000000	USD
CY2021Q4	moh	Amounts Dueto Government Agencies Risk Adjustment AmountsDuetoGovernmentAgenciesRiskAdjustment	902000000	USD
CY2020Q4	moh	Amounts Dueto Government Agencies Risk Adjustment AmountsDuetoGovernmentAgenciesRiskAdjustment	326000000	USD
CY2020Q4	moh	Amounts Dueto Government Agencies Other AmountsDuetoGovernmentAgenciesOther	21000000	USD
CY2021Q4	moh	Amounts Due To Government Agencies Business Combination AmountsDueToGovernmentAgenciesBusinessCombination	0	USD
CY2020Q4	moh	Amounts Due To Government Agencies Business Combination AmountsDueToGovernmentAgenciesBusinessCombination	143000000	USD
CY2021Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	2472000000	USD
CY2020Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	1253000000	USD
CY2021Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	902000000	USD
CY2021Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	7000000	USD
CY2021Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable	895000000	USD
CY2020Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	326000000	USD
CY2020Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	20000000	USD
CY2020Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable	306000000	USD
CY2021Q4	us-gaap	Prepaid Reinsurance Premiums PrepaidReinsurancePremiums	2000000	USD
CY2020Q4	us-gaap	Prepaid Reinsurance Premiums PrepaidReinsurancePremiums	9000000	USD
CY2019Q4	us-gaap	Prepaid Reinsurance Premiums PrepaidReinsurancePremiums	17000000	USD
CY2021	us-gaap	Insurance Recoveries InsuranceRecoveries	33000000	USD
CY2020	us-gaap	Insurance Recoveries InsuranceRecoveries	23000000	USD
CY2019	us-gaap	Insurance Recoveries InsuranceRecoveries	18000000	USD
CY2021Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	51000000	USD
CY2020Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	30000000	USD
CY2019Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	21000000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.
CY2021	moh	Investments Maturity Period InvestmentsMaturityPeriod	P10Y
CY2021	moh	Investments Average Maturity Period InvestmentsAverageMaturityPeriod	P10Y
CY2021	us-gaap	Net Income Loss NetIncomeLoss	659000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	673000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	737000000	USD
CY2020Q4	moh	Shares Outstanding Excluding Restricted Stock Awards SharesOutstandingExcludingRestrictedStockAwards	58000000.0	shares
CY2019Q4	moh	Shares Outstanding Excluding Restricted Stock Awards SharesOutstandingExcludingRestrictedStockAwards	61900000	shares
CY2018Q4	moh	Shares Outstanding Excluding Restricted Stock Awards SharesOutstandingExcludingRestrictedStockAwards	62100000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	500000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3000000.0	shares
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2021	moh	Weighted Average Numberof Shares Share Based Compensation WeightedAverageNumberofSharesShareBasedCompensation	300000	shares
CY2020	moh	Weighted Average Numberof Shares Share Based Compensation WeightedAverageNumberofSharesShareBasedCompensation	100000	shares
CY2019	moh	Weighted Average Numberof Shares Share Based Compensation WeightedAverageNumberofSharesShareBasedCompensation	100000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57800000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59000000.0	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62200000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	800000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	900000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	600000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1400000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58600000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59900000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64200000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.40
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.40
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.25
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.23
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.47
CY2021Q4	moh	Business Combination Number Of Business Combinations BusinessCombinationNumberOfBusinessCombinations	1	business_combination
CY2021	us-gaap	Acquisition Costs AcquisitionCosts	34000000	USD
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	176000000	USD
CY2021	moh	Business Combination Goodwill Deductible For Income Tax Purposes Percentage BusinessCombinationGoodwillDeductibleForIncomeTaxPurposesPercentage	1
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P5Y4M24D
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	58000000	USD
CY2021	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	24000000	USD
CY2020	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	6000000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	3202000000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	47000000	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	47000000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1875000000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	46000000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	46000000	USD
CY2021	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	24000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	3208000000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	3202000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	1826000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	50000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	1875000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	665000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	667000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1667000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1662000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	335000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	335000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	541000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	538000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	3208000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	3202000000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	10000000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	6000000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	13000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1706000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	18000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	677	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	77000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1000000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	142000000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	70000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	21	security
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	212000000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	136000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	822000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	752000000	USD
CY2021Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	427000000	USD
CY2020Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	385000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	205000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	192000000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	632000000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	577000000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	206000000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	216000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	396000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	391000000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000000	USD
CY2021	moh	Depreciation And Amortization Of Capitalized Software DepreciationAndAmortizationOfCapitalizedSoftware	41000000	USD
CY2020	moh	Depreciation And Amortization Of Capitalized Software DepreciationAndAmortizationOfCapitalizedSoftware	38000000	USD
CY2019	moh	Depreciation And Amortization Of Capitalized Software DepreciationAndAmortizationOfCapitalizedSoftware	33000000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	25000000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	17000000	USD
CY2021	us-gaap	Depreciation Depreciation	16000000	USD
CY2020	us-gaap	Depreciation Depreciation	16000000	USD
CY2019	us-gaap	Depreciation Depreciation	21000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P14Y
CY2021	moh	Depreciationand Amortization Continuing Operations DepreciationandAmortizationContinuingOperations	131000000	USD
CY2020	moh	Depreciationand Amortization Continuing Operations DepreciationandAmortizationContinuingOperations	88000000	USD
CY2019	moh	Depreciationand Amortization Continuing Operations DepreciationandAmortizationContinuingOperations	89000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2021Q4	us-gaap	Lessee Finance Lease Remaining Lease Term LesseeFinanceLeaseRemainingLeaseTerm	P17Y
CY2021Q4	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P25Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P14Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.043
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	34000000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	28000000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	25000000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	15000000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	15000000	USD
CY2021	moh	Finance Lease Cost FinanceLeaseCost	40000000	USD
CY2020	moh	Finance Lease Cost FinanceLeaseCost	34000000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	33000000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	30000000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	15000000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	15000000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18000000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	86000000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28000000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	18000000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	7000000	USD
CY2021Q4	moh	Operating Lease Right Of Use Asset Excluding Leases Acquired OperatingLeaseRightOfUseAssetExcludingLeasesAcquired	128000000	USD
CY2020Q4	moh	Operating Lease Right Of Use Asset Excluding Leases Acquired OperatingLeaseRightOfUseAssetExcludingLeasesAcquired	58000000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	128000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	99000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42000000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	134000000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	76000000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	206000000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	216000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	15000000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	219000000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	225000000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	234000000	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	237000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	30000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	29000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	26000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	27000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	24000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	16000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	22000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	23000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	61000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	243000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	163000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	368000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29000000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	134000000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	134000000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	234000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	143000000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	549000000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	692000000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	290000000	USD
CY2021	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Goodwill Goodwill	982000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	501000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	231000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	270000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	432000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	183000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	249000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	59000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	57000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	56000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	55000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	15000000	USD
CY2021	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
CY2021Q4	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	2486000000	USD
CY2020Q4	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	1647000000	USD
CY2019Q4	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	1406000000	USD
CY2021Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	219000000	USD
CY2020Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	157000000	USD
CY2019Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	126000000	USD
CY2021Q4	moh	Capitation Claims Payable CapitationClaimsPayable	82000000	USD
CY2020Q4	moh	Capitation Claims Payable CapitationClaimsPayable	70000000	USD
CY2019Q4	moh	Capitation Claims Payable CapitationClaimsPayable	55000000	USD
CY2021Q4	moh	Other Claims Payable OtherClaimsPayable	576000000	USD
CY2020Q4	moh	Other Claims Payable OtherClaimsPayable	528000000	USD
CY2019Q4	moh	Other Claims Payable OtherClaimsPayable	267000000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3363000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2696000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1854000000	USD
CY2021Q4	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	226000000	USD
CY2020Q4	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	235000000	USD
CY2019Q4	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	132000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2696000000	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	23943000000	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-239000000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	23704000000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	21148000000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	2080000000	USD
CY2021	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	23228000000	USD
CY2021	moh	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments	197000000	USD
CY2021	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	-6000000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3363000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1854000000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	15939000000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-119000000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	15820000000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	13871000000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1507000000	USD
CY2020	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	15378000000	USD
CY2020	moh	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments	294000000	USD
CY2020	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	106000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2696000000	USD
CY2018Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1961000000	USD
CY2019	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	14176000000	USD
CY2019	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-271000000	USD
CY2019	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	13905000000	USD
CY2019	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	12554000000	USD
CY2019	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1482000000	USD
CY2019	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	14036000000	USD
CY2019	moh	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments	0	USD
CY2019	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	24000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1854000000	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-239000000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-119000000	USD
CY2019	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-271000000	USD
CY2021	moh	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims Including Acquisition Adjustment LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment	54039000000	USD
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	2480000000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	51180000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet	54039000000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	51180000000	USD
CY2021Q4	moh	Shortduration Insurance Contracts Liabilityfor Unpaid Claimsand Claim Adjustment Expense Outstanding Liabilities Relatingto Prior Years ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears	6000000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	224000000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Aggregate Reconciling Items ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems	274000000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3363000000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2200000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2200000000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	27000000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	23000000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2173000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2127000000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-25000000	USD
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05375
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15000000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	307000000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	209000000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	281000000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	204000000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	31000000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	26000000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	12000000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9000000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	240000000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	225000000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-17000000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-13000000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5000000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7000000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.014
CY2021	moh	Effective Income Tax Rate Reconciliation Nondeductible Expense Health Insurance Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent	0
CY2020	moh	Effective Income Tax Rate Reconciliation Nondeductible Expense Health Insurance Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent	0.061
CY2019	moh	Effective Income Tax Rate Reconciliation Nondeductible Expense Health Insurance Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.015
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7000000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	6000000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1000000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-24000000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-19000000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	216000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	235000000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	57000000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.006
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.247
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.300
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.242
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	52000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	23000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	15000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	17000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	18000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	9000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	8000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	120000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	98000000	USD
CY2021Q4	moh	Deferred Tax Liabilities Fixed Assets And Intangibles DeferredTaxLiabilitiesFixedAssetsAndIntangibles	1000000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	13000000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	10000000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000000	USD
CY2020Q4	moh	Deferred Tax Liabilities Fixed Assets And Intangibles DeferredTaxLiabilitiesFixedAssetsAndIntangibles	7000000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	12000000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	106000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	69000000	USD
CY2021Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	10000000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	15000000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	5000000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	20000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	20000000	USD
CY2021Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	10000000	USD
CY2020Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	29000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72000000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	68000000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57000000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	53000000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39000000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	37000000	USD
CY2021	moh	Unrecognized Compensation Forfeited Rate UnrecognizedCompensationForfeitedRate	0.113
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P4Y
CY2021	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	65000000	USD
CY2020	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	67000000	USD
CY2019	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	53000000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	124000000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	23000000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	395000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	65.59
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	100000000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	21000000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	405000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	64.79
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	33.02
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	100000000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0	shares
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	41000000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	28000000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	28000000	USD
CY2021Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	23000000	USD
CY2020Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	17000000	USD
CY2021Q4	us-gaap	Special Assessment Bond SpecialAssessmentBond	35000000	USD
CY2021Q4	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	2700000000	USD
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	2900000000	USD
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	2100000000	USD
CY2021	us-gaap	Revenues Revenues	27771000000	USD
CY2020	us-gaap	Revenues Revenues	19423000000	USD
CY2019	us-gaap	Revenues Revenues	16829000000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1020000000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	1078000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	1044000000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-145000000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117000000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-72000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	875000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	961000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	972000000	USD
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001179929-22-000025-index-headers.html	Edgar Link	pending
0001179929-22-000025-index.html	Edgar Link	pending
0001179929-22-000025.txt	Edgar Link	pending
0001179929-22-000025-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
moh-20211231.htm	Edgar Link	pending
moh-20211231.xsd	Edgar Link	pending
moh-20211231_cal.xml	Edgar Link	unprocessable
moh-20211231_def.xml	Edgar Link	unprocessable
moh-20211231_g1.jpg	Edgar Link	pending
moh-20211231_g2.jpg	Edgar Link	pending
moh-20211231_g3.jpg	Edgar Link	pending
moh-20211231_g4.jpg	Edgar Link	pending
moh-20211231_htm.xml	Edgar Link	completed
moh-20211231_lab.xml	Edgar Link	unprocessable
moh-20211231_pre.xml	Edgar Link	unprocessable
moh4q21_ex211.htm	Edgar Link	pending
moh4q21_ex231.htm	Edgar Link	pending
moh4q21_ex311.htm	Edgar Link	pending
moh4q21_ex312.htm	Edgar Link	pending
moh4q21_ex321.htm	Edgar Link	pending
moh4q21_ex322.htm	Edgar Link	pending
moh4q21_examendedandrestat.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MOH
MOLINA HEALTHCARE, INC. Stock $moh

2021 Q4 Form 10-K Financial Statement

#000117992922000025 Filed on February 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH MOLINA HEALTHCARE, INC. Stock $moh

2021 Q4 Form 10-K Financial Statement

#000117992922000025 Filed on February 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH
MOLINA HEALTHCARE, INC. Stock $moh